Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

With the approval of Moderna's updated COVID-19 vaccine, doctors are hoping the shots will be available soon and Albertans ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...

Moderna has vowed to cut annual R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more ...

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...

After being criticized for profligate post-pandemic spending, the company is "pacing" itself to focus on launches of key medicines.

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...